Similarly, primary CML cells, but not normal CD34+ samples, are particularly sensitive to treatment with the arginine‐depleting enzyme, BCT‐100, which induces apoptosis and reduces clonogenicity. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.